SEARCH RESULT

Total Matching Records found : 188

Domestic pharma lauds apex court verdict-Reghu Balakrishnan

-The Business Standard Patients' lobbies cheer ruling on anti-cancer drug Glivec, as affordability and access to life-saving drugs get a leg-up Though the India office here of Swiss pharma giant Novartis wore a gloomy look following the Supreme Court rejection of its Glivec patent application, Indian pharmaceutical companies and patients' associations are in celebration mood. D G Shah, secretary general, The Indian Pharmaceutical Alliance (IPA), comprising leading research-based Indian pharma companies, said,...

More »

Novartis loses patent battle in SC

-The Business Standard Court denies Swiss drug firm patent protection for its anti-cancer drug Glivec; domestic industry hails verdict The Supreme Court on Monday dismissed Novartis AG's appeal for patent protection of its anti-cancer drug, Glivec, putting an end to a seven-year battle between the Swiss drug maker, several domestic generic manufacturers, as well as patient groups fighting for Affordable Medicines. A Bench of judges Aftab Alam and Ranjana Desai said in a...

More »

Novartis order may force pharma MNCs to change

-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...

More »

Patent war over drugs goes chronic -Rupali Mukherjee

-The Times of India MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market. Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster...

More »

European Union-India FTA may hit generic medical industry-Rema Nagarajan

-The Times of India The free trade agreement that European Union is pushing India to sign could put an end to India's status as the pharmacy of the developing providing Affordable Medicines, especially HIV drugs to countries like Brazil, Thailand, South Africa, Zimbabwe and several others. The negotiations with EU are on at a feverish pace this week in Brussels even before the parliamentary standing committee looking into the free trade...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close